Corvus Pharmaceuticals (CRVS)
(Real Time Quote from BATS)
$2.06 USD
+0.04 (1.98%)
Updated May 29, 2024 01:28 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
CRVS 2.06 +0.04(1.98%)
Will CRVS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CRVS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRVS
Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
CRVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
What Makes Corvus (CRVS) a New Buy Stock
Other News for CRVS
Fly Insider: Sensata, BioMarin among week's notable insider trades
Biotech Alert: Searches spiking for these stocks today
Maintaining Neutral: A Balanced View on Corvus Pharmaceuticals Amid Promising Developments and Financial Prudence
Biotech Alert: Searches spiking for these stocks today
NanoViricides, TC BioPharm, Holdco Nuvo among healthcare movers